Literature DB >> 31784408

Caspr2 antibody-associated limbic encephalitis: contribution of visual aided analysis of 18F-FDG PET images using normal database comparison.

Liset Sánchez-Ordúz1, Jaime Gállego Pérez-Larraya2, Fabiana Grisanti3, María Centeno2, Javier Arbizu4.   

Abstract

Early immunotherapy is of paramount importance for a positive outcome in patients suffering acute encephalitis of autoimmune origin (AIE). A new approach for early diagnosis based on clinical presentation and complementary tests has been proposed, but not all these tests show positive findings in the first weeks. While common forms of AIE (anti-LGI-1 and anti-NMDAR antibodies) exhibit consistent 18Fluor-fluorodeoxiglucose (FDG-PET) patterns in many cases, the anti-Caspr2 form of AIE is infrequent and FDG-PET patterns have not been well characterized. In our experience, FDG-PET in anti-Caspr2 limbic encephalitis shows medial temporal hypermetabolism and diffuse cortical hypometabolism, even in the absence of findings in these tests. However, it is necessary to standardize PET image analysis by means of visual and voxel-based methods compared to normal databases to define the areas of pathological metabolism that may go unnoticed when using visual analysis exclusively.
Copyright © 2019 Sociedad Española de Medicina Nuclear e Imagen Molecular. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  (18)F-FDG PET/CT; (18)F-FDG PET/TC; Caspr2; Encefalitis autoinmune; Encefalitis límbica; Limbic encephalitis; autoimmune encephalitis

Mesh:

Substances:

Year:  2019        PMID: 31784408     DOI: 10.1016/j.remn.2019.08.008

Source DB:  PubMed          Journal:  Rev Esp Med Nucl Imagen Mol (Engl Ed)        ISSN: 2253-8089


  1 in total

1.  Possible coexistence of MOG-IgG-associated disease and anti-Caspr2 antibody-associated autoimmune encephalitis: a first case report.

Authors:  Pei Liu; Miao Bai; Xu Yan; Kaixi Ren; Jiaqi Ding; Daidi Zhao; Hongzeng Li; Yaping Yan; Jun Guo
Journal:  Ther Adv Neurol Disord       Date:  2020-10-29       Impact factor: 6.570

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.